David J. Robison has been named president and chief executiveofficer of Calypte Biomedical Corp. of Berkeley, Calif. Robisonwas chief operating officer. Company founder and PresidentHoward B. Urnovitz has been named chairman and willcontinue as chief science officer. Calypte is developing productsfor the early diagnosis and treatment of infectious diseases,initially targeting AIDS.

Allan P. Jarvis has been named vice president of businessplanning at Repligen Corp. He was director of businessdevelopment for Abbott Biotech Inc., a subsidiary of AbbottLaboratories. Repligen (NASDAQ:RGEN) of Cambridge, Mass., isdeveloping an AIDS vaccine and other products.

Genetics Institute Inc. (NASDAQ:GENIZ) of Cambridge, Mass., hasnamed John Petricciani vice president of regulatory affairs. Hewas vice president for medical and regulatory affairs for thePharmaceutical Manufacturers Association.

Crop Genetics International of Hanover, Md., has namedThomas W. Parton to its board. Parton was managing directorof the agricultural division of Ciba-Geigy A.G. until he retiredlast year. Crop Genetics (NASDAQ:CROP) is developing cropprotection systems.

Carl F. Bobkoski, executive vice president of GensiaPharmaceuticals Inc., has been named to the board of the SanDiego-based biopharmaceutical company (NASDAQ:GNSA).

Thomas G. Davis, former vice president of SmithKline BeckmanCorp., has been elected to the board of Celtrix PharmaceuticalsInc. The Palo Alto, Calif., company (NASDAQ:CTRX) is developingtherapeutics based on naturally occurring, cell-regulatingproteins.

Cellcor Inc. of Newton, Mass., has named to its board StephenM. Shortell, A.C. Buehler Distinguished Professor of HealthServices Management at the J.L. Kellogg Graduate School ofManagement of Northwestern University. Cellcor(NASDAQ:CLTX) is focused on living cell therapies.

LifeCell Corp. (NASDAQ:LFCC) of The Woodlands, Texas, hasnamed P. William Curreri consulting director of clinical andregulatory affairs. Curreri, who has been involved inestablishing burn treatment centers, will direct clinical trials ofthe company's skin replacement product.

Michael J. Forrest has been named director of pharmacology atCytel Corp. of San Diego. He was a senior researchpharmacologist and research fellow in the department ofcellular and molecular pharmacology at Merck Sharp & DohmeResearch Laboratories. Cytel (NASDAQ:CTEL) is focused ondrugs to treat immune system disorders and inflammatorydiseases.

Xenova Ltd. of Slough, England, has named Henri A. Termeer,president and chief executive officer of Genzyme Corp., to itsboard as a non-executive director. Xenova is focused onderiving small molecule drugs from microbes.

NeoRx Corp. has named to its scientific advisory boardLawrence A. Loeb, former president of the AmericanAssociation for Cancer Research. The Seattle company(NASDAQ:NERX) develops monoclonal antibodies and imagingagents.

Jerry Caulder, chairman, president and chief executive officerof Mycogen Corp., has been appointed to the newly formedAlternative Agriculture Research and Commercialization Board.The board was designated by Congress under the 1990 FarmBill to establish policy, implement programs and direct theactivities of an independent center within the USDA. Mycogen(NASDAQ:MYCO) of San Diego provides crop protection productsand services.

The Massachusetts Biotechnology Council, an association ofbiotechnology companies, has named Shirley R. Levineadministrative manager. She was communications director atthe Boston University Goldman School of Graduate Dentistry.

(c) 1997 American Health Consultants. All rights reserved.